ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKD Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials Closed $140 million upsized underwritten public offering and concurrent registered direct offering Ended the second quarter with$431.5 million in cash and cash equivalents and marketable securities, supporting operations through projected Phase 3 enrollment completion in mid-2026 WINSTON-SALEM ...